Lead Product(s): Cantrixil
Therapeutic Area: Oncology Product Name: TRE-E-002-1
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Oasmia Pharmaceutical
Deal Size: $46.0 million Upfront Cash: $4.0 million
Deal Type: Licensing Agreement March 01, 2021
Oasmia will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.